Bank of America Corp DE Has $169,000 Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Bank of America Corp DE decreased its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 93.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 17,010 shares of the company's stock after selling 246,592 shares during the quarter. Bank of America Corp DE's holdings in Kodiak Sciences were worth $169,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. PNC Financial Services Group Inc. boosted its position in shares of Kodiak Sciences by 1,501.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after acquiring an additional 2,988 shares in the last quarter. US Bancorp DE bought a new position in shares of Kodiak Sciences during the 4th quarter worth approximately $40,000. Headlands Technologies LLC acquired a new stake in Kodiak Sciences in the 4th quarter valued at $90,000. Fox Run Management L.L.C. bought a new stake in Kodiak Sciences in the fourth quarter valued at $118,000. Finally, Jump Financial LLC bought a new position in shares of Kodiak Sciences during the fourth quarter valued at $147,000. Institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Price Performance

Shares of KOD traded down $0.02 on Thursday, hitting $3.53. The company's stock had a trading volume of 396,337 shares, compared to its average volume of 349,101. The company has a market capitalization of $186.26 million, a PE ratio of -0.97 and a beta of 2.27. Kodiak Sciences Inc. has a fifty-two week low of $1.92 and a fifty-two week high of $11.60. The company has a 50 day moving average price of $3.67 and a 200 day moving average price of $5.23.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.20). On average, equities analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.